Tag: Akrikhin

AKRIKHIN is one of the leading Russian pharmaceutical companies manufacturing affordable, effective and high quality medicinal products.
AKRIKHIN was established in 1936. The company is in the top-5 of largest local pharmaceutical manufacturers in terms of sales and production volume in the Russian pharmaceutical market.
In the company’s product portfolio there are more than 200 medicinal products (over 100 brands) of the main pharmacotherapeutic fields: cardiology, neurology, dermatology, gynecology, pediatrics, ophthalmology, urology. These are medicinal products manufactured by AKRIKHIN or brought to the Russian market in partnership with other companies.
AKRIKHIN produces a wide range of socially significant pharmaceutical drugs, contributing to the development of the Russian health care system. The company is one of the largest Russian manufacturers of medicines included in the list of vital and essential drugs (VED), as well as of medicines for treatment of tuberculosis and diabetes.
AKRIKHIN manufacturing facility is located 20 km from Moscow. The company production includes workshops for manufacturing of medicinal products of almost all forms: tablets, capsules, liniments, ointments, creams, syrups, gels, suppositories, and others. The annual production output is more than 60 million packages. Medicines are produced using foreign equipment, high quality raw materials and the latest technologies. Modern AKRIKHIN warehouse complex holds more than 4,5 thousand pallet positions ensuring proper storage of medicinal products.
Since 2007 Polpharma has been the strategic partner of AKRIKHIN in the Russian pharmaceutical market. Strategic cooperation of AKRIKHIN and Polpharma includes:
the integrated product portfolio,
transfer of production technologies and cooperation in the field of research and development,
access to international standards and management solutions, staff training, exchange programs.

AKRIKHIN ranks second in the Rating of significant Russian pharmaceutical market entities (according to research conducted by Pharmaceutical Bulletin together with RNC Pharma in February 2015).
AKRIKHIN is in the top three of leaders of the rating in the terms of confidence and preference for cooperation among Russian pharmaceutical companies. According to a survey conducted in 2013 by the independent project Centre of Social Economy, AKRIKHIN was ranked third.
Resting upon 80 years of successful business in the Russian pharmaceutical market, the company actively introduces advanced research and production technologies, as well as high corporate management standards.

MSD and AKRIKHIN localized manufacturing of sitagliptin in Russia

MSD, an innovative global pharmaceutical company, and AKRIKHIN, a leading Russian pharmaceutical manufacturer, announced the successful localization of 100 mg finished dosage form of sitagliptin.

Akrikhin starts manufacturing own developed drug

AKRIKHIN begins producing and selling Acriol Pro, a new medicinal product.

Investments in AKRIKHIN amounted to more than 2.6 billion rubles

Denis Chetverikov, the President of AKRIKHIN, presented the strategy and development priorities of the company to Igor Krasavin, the Head of Noginsk district. Mr. Chetverikov paid a particular attenti...

Akrikhin has started a full-cycle production of Simvastatin

AKRIKHIN JSC has successfully launched a full-cycle production of simvastatin (zocor), a medication intended for prevention and treatment of cardiovascular diseases that was developed by MSD — an inte...

AKRIKHIN and Aktivny Komponent signed letter of intent to produce pharmaceuticals

JSC AKRIKHIN and CJSC Aktivny Komponent
Covering mutually beneficial cooperation in the production of pharmaceutical products. The project is designed to support government policy on import substitution and affordable pharmaceuticals, and w...

MSD and Akrikhin co-invest 300 million rubles in innovative medicines production

Companies aim to expand and deepen partnership in the transfer of pharmaceutical technologies MSD, a global healthcare company known as Merck & Co., Inc. in the U.S. and Canada, and the leading...